Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill. It is the second in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020. Eli Lilly ...

Accessibility StatementSkip Navigation The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines Company plans to create 4,615 manufacturing and construction jobs INDIANAPOLIS, Sept. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. This planned next-generation synthetic medicine a ...

每经记者｜陈星 每经编辑｜张海妮 减重药物赛道的较量越来越激烈。 首先是在药物数据上"你来我往"——今年8月，礼来公布ATTAIN-1研究数据，在第72周，礼来在研口服 小分子GLP-1 RA（胰高血糖素样肽-1受体激动剂）药物Orforglipron最高剂量组平均减重12.4kg（降幅 12.4%）。 近期，诺和诺德方面公布了发表在《新英格兰医学杂志》上的口服司美格鲁肽片Ⅲ期试验OASIS 4的结 果。试验结果显示，在64周时，在所有患者依从治疗的情况下，口服司美格鲁肽片25mg组患者实现了 16.6%的平均体重降幅。 其次，MNC（跨国制药企业）也在不断"扫货"GLP-1，随着近日辉瑞宣布以73亿美元收购Metsera，这 一市场的BD（商务拓展）预期和商业化预期都正在被逐步透支。 礼来、诺和诺德"你来我往" 礼来、诺和诺德在GLP-1赛道的竞争愈演愈烈。 礼来公布Orforglipron的Ⅲ期临床研究"ACHIEVE-3"的顶线结果，该结果优于口服司美格鲁肽的结果 后，诺和诺德公布了Ⅲ期试验OASIS 4的结果。在此项为期64周的试验中，口服司美格鲁肽片25mg联合 生活方式干预，在307名肥胖或超重且 ...

ATLANTA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Boys & Girls Clubs of America today announced a $10 million grant from Lilly Endowment Inc. to support more than 250 Boys & Girls Clubs on or near Native lands across the country. The three-year grant will support efforts to help Boys & Girls Clubs of America take bold steps toward expanding the capacity of these Clubs. The goal: provide all youth in and around Native communities with access to high-quality programs and opportunities for success.  Boys & Girls Clu ...

收购交易 - Celltrion美国子公司以3.3亿美元收购礼来旗下Imclone Systems LLC [1] - 交易通过韩国监管文件正式披露 [1]

公司市场进展 - 公司新推出的减肥药物在中国本土市场取得进展 [1] - 公司采用的市场策略正在提升其竞争力 [1] 行业竞争态势 - 公司正加剧与西方竞争对手的市场竞争 [1]

Let's talk with Scott Zary, healthc care director, S&P global ratings. I'll start with is the demand growing, slowing, or about the same for all of these drugs that they are obesity drugs, but people are using them just to look lose weight and feel better. Um, tell me about the demand cycle.Uh, thank you for having me on. I I think every time I look at the forecast for this company, the demand uh for Lily, that is the demand continues to grow for uh GLP1s across the board. So I think um when you look at it, ...

Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here. The second quarter of 2025 endured significant government policy changes and geopolitical events, which resulted in volatility yet ended with robust performance for equity markets. The Fund’s Institutional Class shares posted an absolute positive return of 11.24% in the quarter, but underperformed the benchma ...

公司股价表现 - 过去一个月公司股价上涨约10% [1][7] - 尽管年内股价仍下跌 但近期多个催化剂推动股价走强 [1][7] 口服减肥药研发进展 - 公司正在开发口服GLP-1药物orforglipron 用于糖尿病和体重管理 [2] - 口服药物相比皮下注射具有优势 无需自动注射装置且储存运输要求更宽松 [3] - 患者更偏好口服药物 因为疼痛感更轻且使用更隐蔽 [3] 临床试验结果 - orforglipron在今年公布三项三期临床研究结果 涵盖糖尿病和肥胖症领域 [5] - 在帮助超重或肥胖(非糖尿病)患者方面表现未完全达到华尔街预期 [5] - 在糖尿病患者体重管理方面的最新数据表现强劲 推动股价上涨 [5] 市场前景与审批预期 - 预计orforglipron到2030年可能产生127亿美元收入 [6] - 部分分析师推测该药物可能在年底前获得美国批准 [6] - FDA新加速审批程序可将审查时间从10个月缩短至1-2个月 orforglipron是该计划的主要候选药物 [6] 现有产品优势 - Zepbound皮下注射剂使公司在快速增长的减肥药市场确立领导地位 [2] - Mounjaro糖尿病药物持续产生强劲季度销售额 巩固公司在糖尿病药物市场的领先地位 [2]

Key Points This is a powerful growth-oriented exchange-traded fund (ETF). It holds more than 300 stocks, many of them high-powered tech stocks. Why look for a needle when you can buy the haystack? 10 stocks we like better than Vanguard Index Funds - Vanguard Growth ETF › If you're in the market for a compelling growth stock to invest in before 2025 ends, I'd like to suggest the Vanguard Growth ETF (NYSEMKT: VUG). It's not a standard common stock, though. It's an exchange-traded fund (ETF): a mutu ...